Many traders dream of the day they can close out their positions and realize that one big gain. You've probably heard stories of novice traders who built up their trading accounts from mere thousands into millions.

Biotechnology is a sector where traders seek out these huge profits. For smart traders, this sector can present an incredible area of opportunity, but for those who are not willing to do their homework, it can be a train wreck waiting to happen. We'll use real-life examples to illustrate why this sector can be so appealing and what issues you should consider before putting your capital at risk.

Key Takeaways

  • Investors are often tempted to look at the biotech sector for high return investments.
  • Investing in biotech, however, comes with risks, in part due to the fact that many of the products being researched or developed will never make it to market.
  • Biotech firms face many regulations as well, including from the FDA, which adds risk to the already volatile nature of developing new drugs.
  • The products produced in this sector are complex, where it would take the average investor significant time to understand the factors that affect the product’s chances of success. 
  • Even large financial institutions tend to have a poor track record when it comes to predicting the performance of these companies. 

The Big Win

Few sectors in the market see small single-product companies go from having tiny market capitalizations to having a worth of over hundreds of millions practically overnight. The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough. 

As an example, as you can see in Figure 1, Novavax Inc. (NVAX) rose from a low of $0.74 in August 2005 to a high of $8.31 in March 2006. This is equal to an amazing 1,023% in seven short months. With gains like this, it is easy to see why so many are anxious to put money into this sector.

Figure 1.

Image by Sabrina Jiang © Investopedia 2021

It's Not All Roses

You can't always put down $10,000 and come back in seven months to collect $102,300. Along with the opportunity to make huge gains comes the potential for some very devastating losses. Because most of the companies in this sector are relatively small, with no more than two or three products, news releases concerning their clinical trials and/or approval from the Food and Drug Administration (FDA) is one of the main factors deciding the direction of the company's stock. Companies in this sector can live and die by these announcements.

For example, investors of Threshold Pharmaceuticals (THLD) saw the price of their shares travel to a high of $16.98 in mid-April 2006 only to fall to a low of $3 in mid-May 2006. The major fall was attributed to the termination of the company's clinical trials upon the FDA's request. The 82% drop in roughly one month is a good example of what can happen when a company releases this type of bad news.

Even worse, notice in Figure 2 how the stock gaps down. This means that you have no chance of cutting losses once you've entered the trade. As an example, let's say that you bought the stock at around $15 and had a stop-loss order in for $13. In theory, the stop-loss should limit your loss to around $2 ($15 - $13). In volatile markets like this, however, you can't limit your loss. Your order will get filled at the open price of $3, not the $13 you wanted. 

Figure 2.

Image by Sabrina Jiang © Investopedia 2021

The Illusion of the Story

Many investors get wrapped up in the story of a small biotech firm and convince themselves that the company's product(s) will revolutionize its industry. Some investors even place money into these types of companies simply because they believe that complex products seem so impressive that they must work. It's not that impressive-sounding products can't be successful, but rather that it is extremely difficult for the average investor to get a handle on the probabilities of success for a drug. 

For example, an investor researching Micromet Inc. (MITI) would have read on its Yahoo! Finance page that "its drug development platform is based on its BiTE technology, an antibody-based format that uses the cytotoxic potential of T-cells. The company's principal product candidates include Adecatumumab (MT201), a recombinant human monoclonal antibody.”

This might sound impressive, but do you have any idea what the company does? Perhaps those of you with doctorates in biology understand, but for the average person (or the average analyst), even understanding the product can be difficult. What this means is that you, the investor, are going to have to do a lot of homework to figure out exactly what the product is, what the company's strategic advances are, and what risks are involved in the event that the product does not work. 

Nobody Really Knows, Not Even the Big Guys

Since the companies in this sector can be very complicated, many traders will turn to large financial institutions for guidance. The buy and sell ratings made by these companies can be used as a tool to determine whether or not an investment decision should be made, but as you can see in Figure 3, they can be totally wrong. 

In our first example, an investment bank issued a buy rating on Valentis Inc. (VLTS) on June 23, 2006. Eleven trading days later, the company released bad news about its drug and the stock fell a whopping 79% in one day. What did the firm that issued the buy rating do? They downgraded the stock to a hold rating. That makes you wonder how poorly a company has to perform to get a sell rating. 

Figure 3.

Image by Sabrina Jiang © Investopedia 2021

Another example of poor financial institution advice occurred on December 8, 2005, when a large investment bank issued a buy rating on DOV Pharmaceuticals Inc. (DOVP). At this point in time, the price was approximately $15, but as you can see in Figure 4, this changed within the next few months as the stock dropped off and hit a low of $2.71. On May 17, 2006, the investment bank came out and (again) issued a hold rating, but this rating was not much help to investors as the stock dropped again, to a new low of $1.85 a month later.

Figure 4.

Image by Sabrina Jiang © Investopedia 2021


The biotechnology sector is very exciting and can be very rewarding for those who remain cautious and do their homework. However, it is easy to get caught up in the dream of 1,000% gains, or the intriguing stories of how certain companies' products will change the world. 

It is important to realize that if you are aiming for huge gains in the biotech sector, you likely will encounter some bad trades that will leave you reeling at the reduction of the value of your account. We all know that investors make mistakes and, as shown above, even the big players can see their picks lose most of their value. If the big players can be completely wrong, so can you, so trade with caution and restraint. When it comes to investing in this high-risk sector, it may be wise to use only as much money as you can afford to lose.